THE DEAL, AT A GLANCE
3/4 reviewedBigHat Biosciences
01What it doesBigHat designs protein medicines using software-guided lab experiments to test and improve drug candidates.Source-grounded · automated review · Explore ↗
Checked 2026-10-04 · Review due 2026-10-11
Read supporting source ↗BigHat Biosciences is an AI-native…
02Who is involvedDFJ Growth and Premji Invest co-led; others participated as Series C investors.Source-grounded · automated review · Explore ↗
03What happened$75 million Series C completed September 24, 2026; total funding reached $223 million.Source-grounded · automated review · Explore ↗
Checked 2026-10-04 · Review due 2026-10-11
Read supporting source ↗SAN MATEO, CALIFORNIA - September…
04Why it mattersBigHat Biosciences' $75M Series C supports a financing-stage thesis around AI-designed therapeutics and an agentic data platform for rapid protein design, with value…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
BigHat Biosciences · Financing Record
Explore source-linked visual explanations for BigHat Biosciences. Unsupported claims are withheld while source review continues.
Record 12684 · Recorded date: 2026-09-24
Explore company records →